Analysts at StockNews.com started coverage on shares of Ekso Bionics (NASDAQ:EKSO – Get Rating) in a research report issued on Wednesday. The brokerage set a “sell” rating on the stock.
A number of other research analysts have also recently issued reports on EKSO. HC Wainwright reissued a “buy” rating and issued a $9.00 price objective on shares of Ekso Bionics in a research note on Thursday, March 30th. 500.com reissued a “reiterates” rating on shares of Ekso Bionics in a research note on Friday, April 28th.
Ekso Bionics Stock Down 3.4 %
Shares of EKSO opened at $1.41 on Wednesday. Ekso Bionics has a 12 month low of $1.03 and a 12 month high of $2.95. The firm’s 50 day moving average is $1.54 and its 200-day moving average is $1.49. The stock has a market capitalization of $19.04 million, a PE ratio of -1.25 and a beta of 1.80. The company has a current ratio of 2.89, a quick ratio of 2.30 and a debt-to-equity ratio of 0.17.
Hedge Funds Weigh In On Ekso Bionics
Hedge funds and other institutional investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP acquired a new position in Ekso Bionics in the third quarter valued at $28,000. Strategic Wealth Investment Group LLC increased its stake in Ekso Bionics by 26.4% in the fourth quarter. Strategic Wealth Investment Group LLC now owns 28,336 shares of the company’s stock valued at $46,000 after purchasing an additional 5,917 shares in the last quarter. Legato Capital Management LLC bought a new stake in Ekso Bionics in the fourth quarter valued at $45,000. Renaissance Technologies LLC increased its stake in Ekso Bionics by 153.4% in the second quarter. Renaissance Technologies LLC now owns 44,606 shares of the company’s stock valued at $74,000 after purchasing an additional 27,006 shares in the last quarter. Finally, Essex Investment Management Co. LLC increased its stake in Ekso Bionics by 90.7% in the third quarter. Essex Investment Management Co. LLC now owns 319,673 shares of the company’s stock valued at $499,000 after purchasing an additional 152,028 shares in the last quarter. Institutional investors and hedge funds own 12.74% of the company’s stock.
About Ekso Bionics
Ekso Bionics Holdings, Inc engages in the design, development and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. It operates through the following segments: EksoHealth and EksoWorks. The EksoHealth segment consists of the engineering, manufacture, and sale of exoskeletons for applications in the medical markets.
- Get a free copy of the StockNews.com research report on Ekso Bionics (EKSO)
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
- Best Buy’s Comeback Is Still At Play, Earnings Call For Patience
- e.l.f. Beauty Has Giant Quarter, Shares Hit New High
- If You Can Only Pick One Stock For The Rest Of 2023, Pick Nvidia
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.